JPRN-UMIN000016768CompletedPhase 1
To investigate efficacy and safety of TAK-750 - To investigate efficacy and safety of TAK-750 (H7N9-TAK-P12)
Clinical Research Center, National Hospital Organization0 sites50 target enrollmentStarted: March 11, 2015Last updated:
Conditions
Trial Snapshot
- Phase
- Phase 1
- Status
- Completed
- Sponsor
- Enrollment
- 50
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 20years-old to ot applicable (—)
- Sex
- All
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1) Individuals with the history of Avian Influenza A (H7) virus infection. (hearing from subjects) 2) Individuals, who had history of anaphylaxis to foods or medicines previously. 3) Individuals with severe diseases in cardiovascular, blood, respiratory, liver, kidney, digestive or neurological systems in their clinical recording. 4) Individuals with a history of acute disseminated encephalomyelitis and Guillain-Barre syndrome in the past. 5) Individuals participated in a clinical trial within four months (counted from the date of vaccination). 6) Individuals vaccinated with live vaccine within 27 days, or received a dose of inactivated vaccine within six days (including the day of vaccination). 7) Individuals received with gamma globulin or blood transfusion within three months, or received the formulation of high dose of gamma globulin therapy (200 mg/kg or more) within six months (including the day of vaccination). 8) From the day of the first administration to the last day of follow-up, Individuals or partners, who wish to become pregnant , and Individuals , who could not perform the appropriate method of contraception. 9)A breast-feeding women, a pregnant women or a suspected pregnancy woman 10) Individuals, who are deemed to be inappropriate by the investigator.
Investigators
Similar Trials
Active, not recruiting
Phase 1
Phase II randomized comparative trial of TAK-700 (Orteronel) versus bicalutamide in metastatic prostate cancer patients failing 1st line treatment with LHRH analogs or surgical castration.metastatic prostate cancer patients failing 1st line treatment with LHRH analogs or surgical castrationMedDRA version: 14.1Level: PTClassification code 10036909Term: Prostate cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-002122-67-BEEORTC200
Active, not recruiting
Not Applicable
Phase II randomized comparative trial of TAK-700 (Orteronel) versus bicalutamide in metastatic prostate cancer patients failing 1st line treatment with LHRH agonists or surgical castration.EUCTR2012-002122-67-ESEuropean Organisation for Research and Treatment of Cancer (EORTC)200
Active, not recruiting
Not Applicable
Phase II randomized comparative trial of TAK-700 (Orteronel) versus bicalutamide in metastatic prostate cancer patients failing 1st line treatment with LHRH analogs or surgical castration.metastatic prostate cancer patients failing 1st line treatment with LHRH analogs or surgical castrationMedDRA version: 16.1Level: PTClassification code 10036909Term: Prostate cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-002122-67-ITEORTC200
Terminated
Phase 3
Efficacy and Safety of TAK-875 Compared to Glimepiride When Used With Metformin in Participants With Type 2 DiabetesDiabetes Mellitus, Type 2NCT01481116Takeda2,454
Withdrawn
Phase 1
A Study to Evaluate the Safety, Pharmacokinetics (PK), and Efficacy of TAK-671 for the Treatment of Coronavirus Disease (COVID) 2019 in AdultsCoronavirus DiseaseNCT04464460Takeda